Skip to main content
. Author manuscript; available in PMC: 2018 Jan 9.
Published in final edited form as: Cancer Res. 2017 Mar 1;77(10):2735–2745. doi: 10.1158/0008-5472.CAN-16-1602

Figure 2.

Figure 2

IL33 promotes colon cancer stemness. A and B, Effects of IL33 on colon cancer sphere formation. Primary colorectal cancer cells (A) and HT-29 cells (B; 4,000 cells) were subject to sphere assay for 7 days. IL33 was added on day 1 and 3. Representative images of spheres of primary colorectal cancer cells are shown (A, left). Scale bar, 50 μm. Results are expressed as the mean numbers of spheres ± SEM and the mean diameters of spheres ± SEM. Each column represents three independent experiments; n = 4; *, P < 0.05; **, P < 0.01. C and D, Effects of IL33 on colon cancer chemotherapy. Primary colorectal cancer cells (C) and HT-29 (D) were cultured with or without IL33 (100 ng/mL) for 24 hours and were subsequently exposed to 5-FU for 24 hours. The cell viability was determined by CCK-8 assay. Results are expressed as the mean ± SEM; n = 7; *, P < 0.05. E and F, Effects of IL33 on core stem cell gene expression in colon cancer cells. Primary colorectal cancer cells were treated with IL33 (100 ng/mL) for 24 hours. The levels of core stem cell gene transcripts (E) and proteins (F) were detected by real-time PCR and Western blotting, respectively. Each column represents three independent experiments. Results are expressed as the mean ± SEM; n = 4; *, P < 0.05.